Item 7.01 Regulation FD Disclosure
On
To the extent that the information in this report and Exhibit 99.1 are not
descriptions of historical facts regarding the Company, they are forward-looking
statements reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. We may, in some cases, use terms such as "predicts,"
"forecasts," "believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might," "should"
or other words that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Examples of forward-looking statements
contained in this report and Exhibit 99.1 include, among others, statements
regarding financial guidance for Xtampza ER and Nucynta Franchise revenues,
adjusted EBITDA, total operating expenses, current and future market
opportunities for our products and our assumptions related thereto. Such
statements are subject to numerous important factors, risks and uncertainties
that may cause actual events or results, performance, or achievements to differ
materially from the company's current expectations. Management's expectations
and, therefore, any forward-looking statements in this press release could also
be affected by risks and uncertainties relating to a number of other factors,
including the impact of the COVID-19 pandemic on our ability to conduct our
business, reach our customers, and supply the market with our products; our
ability to commercialize and grow sales of our products; our ability to manage
our relationships with licensors; the success of competing products that are or
become available; our ability to obtain and maintain regulatory approval of our
products and any product candidates, and any related restrictions, limitations,
and/or warnings in the label of an approved product; the size of the markets for
our products and product candidates, and our ability to service those markets;
our ability to obtain reimbursement and third-party payor contracts for our
products; the rate and degree of market acceptance of our products and product
candidates; the costs of commercialization activities, including marketing,
sales and distribution; changing market conditions for our products; the outcome
of any patent infringement, opioid-related or other litigation that may be
brought by or against us, including litigation with
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release, datedJanuary 6, 2021 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source